Lyrica is a Schedule V controlled substance
Executive Summary
Pfizer plans to launch Lyrica (pregabalin) in the fall following DEA's July 28 final rule classifying the drug as a Schedule V controlled substance. Launch of the gabapentin follow-on has been delayed by the scheduling process. FDA cleared pregabalin in December for neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia; Lyrica added an indication for partial onset seizures in June (1"The Pink Sheet" June 20, 2005, In Brief)...
You may also be interested in...
Lyrica adds third indication
Pfizer's Lyrica (pregabalin) clears FDA June 10 for treatment of partial onset seizures. The Neurontin follow-on was approved for diabetic peripheral neuropathy and postherpetic neuralgia in December 2004 (1"The Pink Sheet" Jan. 10, 2005, p. 5). Lyrica's launch is awaiting final Drug Enforcement Agency scheduling. Pfizer says pregabalin will be available in pharmacies in the fall...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.